TY - JOUR T1 - Can a rapid-access vascular limb salvage service improve one-year amputation outcomes for patients with chronic limb-threatening ischaemia? JF - medRxiv DO - 10.1101/19013037 SP - 19013037 AU - A.T.O. Nickinson AU - J. Dimitrova AU - J.S.M. Houghton AU - L. Rate AU - S. Dubkova AU - H. Lines AU - L.J. Gray AU - S. Nduwayo AU - T. Payne AU - R.D. Sayers AU - R.S.M. Davies Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/19/19013037.abstract N2 - Background Vascular limb salvage services can potentially improve outcomes for patients with chronic limb-threatening ischaemia (CLTI), although their description within the literature is limited. This study aims to evaluate the 12-month outcomes for an outpatient-based vascular limb salvage (VaLS) clinic and investigate times-to-treatment.Methods An analysis of a prospectively maintained database, involving all patients diagnosed with CLTI within the VaLS clinic from February 2018-February 2019, was undertaken. Data were compared to two comparator cohorts, identified from coding data; 1) patients managed prior to the clinic, between May 2017-February 2018 (Pre-Clinic’ [PC]), and 2) patients managed outside of clinic, between February 2018-February 2019 (‘Alternative Pathways’ [AP]). Freedom from major amputation at 12 months was the primary outcome. Kaplan-Meier plots and adjusted Cox’s proportional hazard models (aHR) were utilised to compare outcomes.Results Five-hundred and sixty-six patients (VaLS=158, AP=173, PC=235) were included (median age=74 years). Patients managed within the VaLS cohort were significantly more likely to be free from major amputation (90.5%) compared to both the AP (82.1%, aHR 0.52, 95% CI 0.28-0.98, p=.041) and the PC (80.0%; aHR 0.50, 95% CI 0.28-0.91, p=.022) cohorts at 12 months, after adjustment for age, disease severity and presence of diabetes.Conclusions A limb salvage clinic may help improve the rate of major amputation and provides a reproducible model which delivers timely vascular assessment in an ambulatory setting. Further evaluation is required to assess longer-term outcomes.Competing Interest StatementRSMD has received personal fees for speaking from Cook Medical and Gore, and has received sponsorship from TerumoAortic to run educational workshops. These are outside of the submitted work. The other authors have nothing to declareFunding StatementATON, JD, LR, SD, HL, JSMH, SN and TP are funded through the George Davies Charitable Trust (Registered Charity Number: 1034818). RDS is part funded through this Trust. The funders had no role in the design and conduct of the study, the collection, analysis, and interpretation of the data, or the preparation, review, or approval of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFurther details on methods, data and materials used will be considered upon email request. ER -